Furthermore, T2DM patients receiving SGLT2i displayed higher hyperlipidemia, coronary artery disease, and were taking more GLP-1 agonists, insulin, metformin, statins, aspirin, and ACEI/ARB medications. Here, INS is linked to type 2 diabetes mellitus.